When business operations are resumed in times of the Corona pandemic, safety and health protection have top priority. For this reason, the nationwide occupational health and safety standard COVID-19 has been in force since April 16, 2020.
Hydroxychloroquine is a drug that is indicated for the treatment of malaria and a number of autoimmune diseases such as lupus or rheumatoid arthritis. It is currently under research for the treatment of severe cases of pneumonia caused by Covid-19. Although the results are not yet conclusive, it is already being used in countries such as China, France and Italy for the treatment of corona.
In view of the increased demand and growing concerns about emerging capacity constraints for the drug hydroxychloroquine in Spain, Aristo Pharma has donated its entire current stock of hydroxychloroquine with over 200,000 doses to the Spanish National Health Service (SNS) for research or treatment of patients infected with the new corona virus.
In addition, Aristo Pharma is currently working at its Spanish production facility Medinsa to ensure the supply of other important drugs that play a key role in the treatment of coronavirus symptoms, such as paracetamol and antibiotics.